CV Sciences, Inc. (CVSI)

OTCMKTS · Delayed Price · Currency is USD
0.0290
-0.0010 (-3.33%)
May 26, 2026, 11:55 AM EST
Market Cap6.01M +12.6%
Revenue (ttm)13.38M -12.6%
Net Income-1.49M
EPS-0.01
Shares Out 197.33M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Open0.0288
Previous Close0.0300
Day's Range0.0288 - 0.0290
52-Week Range0.0230 - 0.1000
Beta0.45
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About CV Sciences

CV Sciences, Inc. engages in the development, manufacture, marketing, and sale of herbal supplements, hemp-based cannabidiol (CBD), and plant-based food products in North America. It offers its products under the PlusCBD, PlusCBD Pet, PlusHLTH, Cultured Foods, and Lunar Fox brand names in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, select distributors, brick and mortar retailers, and select e-tailers. The company was formerly known as CannaVest Corp. and changed it... [Read more]

Sector Healthcare
Founded 2010
Employees 44
Stock Exchange OTCMKTS
Ticker Symbol CVSI
Full Company Profile

Financial Performance

In 2025, CV Sciences's revenue was $13.79 million, a decrease of -12.20% compared to the previous year's $15.71 million. Losses were -$958,000, -59.98% less than in 2024.

Financial Statements

News

CV Sciences Earnings Call Transcript: Q1 2026

Revenue declined 11% year-over-year to $3.2 million, but gross margin improved to 48.9% and operating expenses fell 13%. Adjusted EBITDA loss narrowed to $0.1 million, and positive operating cash flow was achieved. Regulatory and market headwinds persist.

11 days ago - Transcripts

CV Sciences Earnings release: Q1 2026

CV Sciences released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.

11 days ago - Filings

CV Sciences Quarterly report: Q1 2026

CV Sciences has published its Q1 2026 quarterly earnings report on May 14, 2026.

11 days ago - Filings

CV Sciences, Inc. Reports First Quarter-End 2026 Financial Results

SAN DIEGO, CA / ACCESS Newswire / May 14, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extract...

12 days ago - Accesswire

CV Sciences, Inc. To Announce First Quarter 2026 Results On May 14, 2026

SAN DIEGO, CA / ACCESS Newswire / May 12, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extract...

13 days ago - Accesswire

CV Sciences Proxy statement: Proxy filing

CV Sciences filed a proxy statement on April 15, 2026, providing details for shareholder voting and corporate governance matters.

5 weeks ago - Filings

CV Sciences Earnings Call Transcript: Q4 2025

Revenue declined to $13.8M in 2025, but gross margin rose to 49% and cost reductions drove positive Q4 adjusted EBITDA. New product launches, acquisitions, and regulatory changes position the company for growth and improved cash flow in 2026.

2 months ago - Transcripts

CV Sciences Annual report: Q4 2025

CV Sciences has published its Q4 2025 annual report on March 26, 2026.

2 months ago - Filings

CV Sciences Earnings release: Q4 2025

CV Sciences released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.

2 months ago - Filings

CV Sciences, Inc. Reports Fiscal Year-End 2025 Financial Results

SAN DIEGO, CA / ACCESS Newswire / March 26, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...

2 months ago - Accesswire

CV Sciences, Inc. To Announce Year End and Fourth Quarter 2025 Results On March 26, 2026

SAN DIEGO, CA / ACCESS Newswire / March 24, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp extra...

2 months ago - Accesswire

CV Sciences Announces Successful Debt Restructuring Designed to Strengthen Financial Position and Fuel Future Growth

SAN DIEGO, CA / ACCESS Newswire / March 10, 2026 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in proven, sc...

2 months ago - Accesswire

CV Sciences launches EMPOWR protein, creatine powder

CV Sciences (CVSI) announced the launch of Empowr, a plant-based protein and creatine powder for everyday adults looking to increase daily protein intake for overall wellness. “Empowr” represents a dy...

3 months ago - TheFly

CV Sciences Launches EMPOWR: A Plant-Based Protein + Creatine Formula Designed for Total Wellness

With 20g of clean protein, 5g of creatine, and LactoSpore® probiotics, Empowr supports everyday strength, mental energy and digestive balance without dairy or added sugar. Simple, functional nutrition...

3 months ago - Accesswire

CV Sciences, Inc. Positioned to Participate in the Medicare and Medicaid Pilot Program for CBD

SAN DIEGO, CA / ACCESS Newswire / December 22, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...

5 months ago - Accesswire

President Trump says marijuana order ‘not legalization’

President Trump is signing an executive order to reschedule marijuana for “legitimate medical uses.” Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), ...

5 months ago - TheFly

Trump says looking at reclassifying mariijuana ‘very strongly,’ Bloomberg says

Publicly traded companies in the cannabis space include Aurora Cannabis (ACB), CV Sciences (CVSI), Canopy Growth (CGC), Cronos Group (CRON), Goodness Growth (GDNSF), Green Thumb Industries (GTBIF), IG...

5 months ago - TheFly

CV Sciences Earnings Call Transcript: Q3 2025

Q3 2025 revenue declined 16% year-over-year to $3.3 million, with gross margin improving to 48.5%. Regulatory uncertainty and out-of-stock issues impacted sales, but cost controls and acquisition integration position the company for positive cash flow and growth in 2026.

6 months ago - Transcripts

CV Sciences Quarterly report: Q3 2025

CV Sciences has published its Q3 2025 quarterly earnings report on November 13, 2025.

6 months ago - Filings

CV Sciences Earnings release: Q3 2025

CV Sciences released its Q3 2025 earnings on November 13, 2025, summarizing the period's financial results.

6 months ago - Filings

CV Sciences, Inc. Reports Third Quarter 2025 Financial Results

SAN DIEGO, CA / ACCESS Newswire / November 13, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in hemp ex...

6 months ago - Accesswire

CV Sciences, Inc. to Announce Third Quarter 2025 Results on November 13, 2025

SAN DIEGO, CALIFORNIA / ACCESS Newswire / November 10, 2025 / CV Sciences, Inc. (OTCQB:CVSI) (the "Company", "CV Sciences", "our", "us" or "we"), a preeminent consumer wellness company specializing in...

7 months ago - Accesswire

CV Sciences Launches Ignite: A Men's Performance Formula for Vitality, Recovery, Libido & Focus

Ignite delivers a powerful blend of proven botanicals along with our award-winning CBD, designed to help men stay strong, sharp, and ready-at work, in the gym, and beyond. SAN DIEGO, CALIFORNIA / ACCE...

9 months ago - Accesswire

CV Sciences Earnings Call Transcript: Q2 2025

Q2 2025 saw flat sequential revenue at $3.6M, a record 50.9% gross margin, and first positive adjusted EBITDA since 2019. Cost efficiency, new product launches, and M&A integration drove margin gains despite regulatory headwinds.

10 months ago - Transcripts

CV Sciences Quarterly report: Q2 2025

CV Sciences has published its Q2 2025 quarterly earnings report on August 13, 2025.

10 months ago - Filings